Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
TREMELIMUMAB-ACTL 300 MG/15ML IV SOLN (NDC 00310453530) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved October 15, 2026 , from http://ppman.hank.ai/transparency/procedure/00310453530/by-state?code_type=NDC
“TREMELIMUMAB-ACTL 300 MG/15ML IV SOLN (NDC 00310453530) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/00310453530/by-state?code_type=NDC. Accessed
October 15, 2026 .
“TREMELIMUMAB-ACTL 300 MG/15ML IV SOLN (NDC 00310453530) by State,” HANK Price Transparency ,
accessed October 15, 2026 ,
http://ppman.hank.ai/transparency/procedure/00310453530/by-state?code_type=NDC.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
NDC · across United States
00310453530 — Tremelimumab-actl 300 Mg/15ml IV Soln
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$37,433
National median
$50 – $83,538
IQR (p25 – p75)
17
hospitals filing
5
states
Walking in without insurance?
Cash / self-pay price
Cash median
$46,582
vs. negotiated
+24.4%
Hospitals reporting
25
Cash / self-pay rates apply when you don't run the bill through insurance.
Many hospitals also offer income-based discounts on top of the published
cash price — always ask about a financial-assistance application
before paying.
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 00310453530 (NDC), with interquartile range
State Median p25 p75
CA $83,538 $60,267 $89,505
MI $64,053 $51,457 $79,991
OH $51,380 $135 $71,736
OR $131 $61 $146
FL $1 $1 $2